BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 34880120)

  • 21. A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.
    Battaglini E; Park SB; Barnes EH; Goldstein D
    Contemp Clin Trials; 2018 Jul; 70():135-138. PubMed ID: 29680317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analgesic efficacy of pregabalin administered according to either a prevention protocol or an intervention protocol in rats with cisplatin-induced peripheral neuropathy.
    Han FY; Kuo A; Nicholson JR; Corradinni L; Smith MT
    Clin Exp Pharmacol Physiol; 2018 Oct; 45(10):1067-1075. PubMed ID: 29781509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
    Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
    Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity.
    Sałat K
    Pharmacol Rep; 2020 Jun; 72(3):508-527. PubMed ID: 32347537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Microglial Activation Inhibitor Minocycline, Used Alone and in Combination with Duloxetine, Attenuates Pain Caused by Oxaliplatin in Mice.
    Sałat K; Furgała-Wojas A; Sałat R
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34208184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol.
    Jang CE; Jung MS; Sohn EH; Kim M; Yoo HS; Bae K; Kim JR; Lee JS
    Trials; 2018 Sep; 19(1):526. PubMed ID: 30268158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy.
    Kanbayashi Y; Inagaki M; Ueno H; Hosokawa T
    Med Oncol; 2017 Aug; 34(8):137. PubMed ID: 28687964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.
    Hiramoto S; Asano H; Miyamoto T; Takegami M; Kawabata A
    PLoS One; 2021; 16(12):e0261473. PubMed ID: 34972132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosmarinic Acid Mitigates Mitochondrial Dysfunction and Spinal Glial Activation in Oxaliplatin-induced Peripheral Neuropathy.
    Areti A; Komirishetty P; Kalvala AK; Nellaiappan K; Kumar A
    Mol Neurobiol; 2018 Sep; 55(9):7463-7475. PubMed ID: 29427084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duloxetine, a Balanced Serotonin-Norepinephrine Reuptake Inhibitor, Improves Painful Chemotherapy-Induced Peripheral Neuropathy by Inhibiting Activation of p38 MAPK and NF-κB.
    Meng J; Zhang Q; Yang C; Xiao L; Xue Z; Zhu J
    Front Pharmacol; 2019; 10():365. PubMed ID: 31024320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orally active Epac inhibitor reverses mechanical allodynia and loss of intraepidermal nerve fibers in a mouse model of chemotherapy-induced peripheral neuropathy.
    Singhmar P; Huo X; Li Y; Dougherty PM; Mei F; Cheng X; Heijnen CJ; Kavelaars A
    Pain; 2018 May; 159(5):884-893. PubMed ID: 29369966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.
    Hopkins HL; Duggett NA; Flatters SJL
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):119-128. PubMed ID: 27054288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The analgesic effect of orexin-A in a murine model of chemotherapy-induced neuropathic pain.
    Toyama S; Shimoyama N; Shimoyama M
    Neuropeptides; 2017 Feb; 61():95-100. PubMed ID: 28041630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity.
    Illias AM; Gist AC; Zhang H; Kosturakis AK; Dougherty PM
    Pain; 2018 Jul; 159(7):1308-1316. PubMed ID: 29554018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy.
    Zhang H; Li Y; de Carvalho-Barbosa M; Kavelaars A; Heijnen CJ; Albrecht PJ; Dougherty PM
    J Pain; 2016 Jul; 17(7):775-86. PubMed ID: 26979998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of TACAN, a Mechanotransducing Ion Channel, in Inflammatory But Not Neuropathic Hyperalgesia in the Rat.
    Bonet IJM; Araldi D; Bogen O; Levine JD
    J Pain; 2021 May; 22(5):498-508. PubMed ID: 33232830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review.
    Flatters SJL; Dougherty PM; Colvin LA
    Br J Anaesth; 2017 Oct; 119(4):737-749. PubMed ID: 29121279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
    Smith EM; Pang H; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Fadul CE; Knox C; Le-Lindqwister N; Gilman PB; Shapiro CL;
    JAMA; 2013 Apr; 309(13):1359-67. PubMed ID: 23549581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention and treatment of chemotherapy-induced peripheral neuropathy.
    Piccolo J; Kolesar JM
    Am J Health Syst Pharm; 2014 Jan; 71(1):19-25. PubMed ID: 24352178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.